While SGLT2-i therapy may occasionally lead to acute renal impairment in patients predisposed to volume depletion [6,7], none of these patients met the criteria for acute kidney injury according to the RIFLE classification (>50% acute decline in eGFR) [23]. The gene discussed is SLC5A2; the disease is acute kidney injury.